The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Commentary|Articles|June 2, 2026
Dr Eads on Early Data for CDH17-Directed CAR T-Cell Therapy in R/R GI Cancers
Author(s)Jennifer Eads, MD
Fact checked by: Chris Ryan, Ashling Wahner
Jennifer Eads, MD, discusses data for the CAR T-cell therapy CHM-2101 in relapsed/refractory GI cancers.
Advertisement
Jennifer Eads, MD, a professor of clinical medicine (hematology-oncology), physician lead for Gastrointestinal (GI) Clinical Research, and director of the National Clinical Trials Network at Abramson Cancer Center of the University of Pennsylvania, discussed early data from a phase 1/2 trial (NCT06055439) evaluating the CDH17-directed CAR T-cell therapy CHM-2101 for the treatment of patients with relapsed/refractory GI cancers.
Advertisement
Related to this article
The TRIPP-FFX trial met its primary end points of local disease control and safety with P-32 microparticles plus FOLFIRINOX pancreatic adenocarcinoma.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
Phase 1/2 data from 2 trials showed high ORRs with zoldonrasib-based regimens in first-line and previously treated RAS G12D metastatic pancreatic ductal adenocarcinoma.
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
In EMERALD-3, STRIDE with or without lenvatinib plus TACE improved PFS, ORR, and DOR vs TACE alone by RECIST 1.1 and mRECIST criteria in HCC.
Updated data from the GALAXY study showed an association between postsurgical MRD positivity per Signatera and OS benefit with adjuvant chemotherapy.
First-line domvanalimab plus zimberelimab and chemotherapy did not improve OS vs nivolumab plus chemotherapy in HER2-negative gastroesophageal cancer.
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 7/12
2
Five Under 5: Top Oncology Videos for the Week of 7/12
3
Frontline Sac-TMT Plus Pembrolizumab Meets PFS End Point in PD-L1–Negative, Nonsquamous NSCLC
4
Imaging Cadence, Radiation Timing, and Osimertinib Dosing Frame CNS Management Decisions in EGFR-Mutated NSCLC
5